• Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®).

  • Our SCS Microinjector® enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

  • We have a pipeline of small molecule product candidates for administration via our SCS Microinjector. Our Phase 3 ready asset, CLS-AX (axitinib injectable suspension), is targeting the treatment of wet AMD.
  • Our first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food & Drug Administration in October 2021 and is available in the U.S. through a commercial partner.
  • We have multiple strategic partners utilizing our SCS injection platform technology to deliver their ophthalmic therapeutic innovations.

PIONEERING THE WAY

Clearside’s Suprachoroidal Space (SCS®) Injection Platform

Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations, that can be delivered via suprachoroidal administration.

Proven Commercial Capabilities in Suprachoroidal Delivery

COLLABORATIONS

We strategically partner our SCS® injection platform with companies utilizing other ophthalmic therapeutic innovations. Our decision to selectively partner our proprietary technology has validated our investment in suprachoroidal delivery using our SCS Microinjector® and has expanded our overall development and commercialization pipeline.